Af­ter mul­ti­ple clin­i­cal tri­al fail­ures, Fi­bro­Gen lays off one-third of staff

Fi­bro­Gen is lay­ing off 104 em­ploy­ees in the US, it dis­closed in an SEC fil­ing Wednes­day morn­ing.

That equates to 32% of its work­force, the biotech said. In late June, Fi­bro­Gen fore­shad­owed that lay­offs would be com­ing af­ter its an­ti­body drug pam­revlum­ab failed a Phase III study in id­io­path­ic pul­monary fi­bro­sis — the biotech’s third late-stage tri­al fail­ure in two months.

Now, Fi­bro­Gen ex­pects that it will have enough run­way to last in­to 2026. Pre­vi­ous­ly, the Bay Area biotech said that it had enough cash to op­er­ate through 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER